Cronos Group
Market Cap
CA$2.4b
Last Updated
2020/09/26 06:11 UTC
Data Sources
Company Financials +
Executive Summary
Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 34.3% per year for the next 3 years
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Cronos Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRON's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.4%
CRON
-7.4%
CA Pharmaceuticals
-2.3%
CA Market
1 Year Return
-43.8%
CRON
-42.9%
CA Pharmaceuticals
-8.6%
CA Market
Return vs Industry: CRON matched the Canadian Pharmaceuticals industry which returned -42.9% over the past year.
Return vs Market: CRON underperformed the Canadian Market which returned -8.6% over the past year.
Shareholder returns
| CRON | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.4% | -7.4% | -2.3% |
| 30 Day | -4.2% | -12.7% | -4.5% |
| 90 Day | -17.2% | -1.0% | 5.7% |
| 1 Year | -43.8%-43.8% | -42.9%-42.9% | -5.5%-8.6% |
| 3 Year | 160.2%160.2% | -23.9%-24.6% | 5.8%-4.4% |
| 5 Year | 2,325.0%2,325.0% | 288.2%288.2% | 38.3%17.1% |
Price Volatility Vs. Market
How volatile is Cronos Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Have Insiders Been Buying Cronos Group Inc. (TSE:CRON) Shares This Year?3 months ago | Simply Wall St
Can We See Significant Institutional Ownership On The Cronos Group Inc. (TSE:CRON) Share Register?2 years ago | Simply Wall St
Is Cronos Group Inc's (TSE:CRON) Balance Sheet Strong Enough To Weather A Storm?Valuation
Is Cronos Group undervalued compared to its fair value and its price relative to the market?
2.59x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CRON (CA$6.79) is trading above our estimate of fair value (CA$1.82)
Significantly Below Fair Value: CRON is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRON is good value based on its PE Ratio (2.6x) compared to the CA Pharmaceuticals industry average (18.9x).
PE vs Market: CRON is good value based on its PE Ratio (2.6x) compared to the Canadian market (16.1x).
Price to Earnings Growth Ratio
PEG Ratio: CRON's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: CRON is good value based on its PB Ratio (1.1x) compared to the CA Pharmaceuticals industry average (1.3x).
Next Steps
Future Growth
How is Cronos Group forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
-34.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRON's earnings are forecast to decline over the next 3 years (-34.3% per year).
Earnings vs Market: CRON's earnings are forecast to decline over the next 3 years (-34.3% per year).
High Growth Earnings: CRON's earnings are forecast to decline over the next 3 years.
Revenue vs Market: CRON's revenue (43.2% per year) is forecast to grow faster than the Canadian market (5.2% per year).
High Growth Revenue: CRON's revenue (43.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRON is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Cronos Group performed over the past 5 years?
84.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRON has high quality earnings.
Growing Profit Margin: CRON's current net profit margins are lower than last year .
Past Earnings Growth Analysis
Earnings Trend: CRON has become profitable over the past 5 years, growing earnings by 84.6% per year.
Accelerating Growth: CRON's earnings growth over the past year (30.9%) is below its 5-year average (84.6% per year).
Earnings vs Industry: CRON earnings growth over the past year (30.9%) exceeded the Pharmaceuticals industry 18.3%.
Return on Equity
High ROE: CRON's Return on Equity (38.1%) is considered high.
Next Steps
Financial Health
How is Cronos Group's financial position?
Financial Position Analysis
Short Term Liabilities: CRON's short term assets ($1.4B) exceed its short term liabilities ($235.2M).
Long Term Liabilities: CRON's short term assets ($1.4B) exceed its long term liabilities ($12.0M).
Debt to Equity History and Analysis
Debt Level: CRON is debt free.
Reducing Debt: CRON has no debt compared to 5 years ago when its debt to equity ratio was 15.6%.
Debt Coverage: CRON has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRON has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Cronos Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRON's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.9yrs
Average management tenure
CEO
Kurt Schmidt (63 yo)
no data
Tenure
Mr. Kurt Thomas Schmidt, B.Sc., MBA, serves as President and Chief Executive Officer at Cronos Group Inc. since September 9, 2020. He has been Independent Director of Campbell Soup Company since November 2 ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | US$11.33m | 0.55% $ 12.9m | |
| Chief Financial Officer | 1.42yrs | US$601.02k | 0% $ 0 | |
| Executive VP of Legal and Regulatory Affairs & Corporate Secretary | 2.92yrs | US$491.57k | 0% $ 0 | |
| President & CEO | no data | no data | no data | |
| Director of Investor Relations & Strategy | 0.67yr | no data | no data | |
| Head of Marketing | no data | no data | no data | |
| Senior Vice President of Corporate Affairs | 0.50yr | no data | 0.0029% $ 67.9k | |
| Chief Innovation Officer | 1.17yrs | no data | 0.0043% $ 101.9k | |
| VP & Controller | no data | no data | no data | |
| General Manager of USA | 0.67yr | no data | no data | |
| Vice President of Finance | no data | no data | no data |
0.9yrs
Average Tenure
36yo
Average Age
Experienced Management: CRON's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | US$11.33m | 0.55% $ 12.9m | |
| Independent Director | 1.5yrs | US$150.74k | no data | |
| Independent Lead Director | 2.33yrs | US$162.05k | 0.010% $ 246.1k | |
| Independent Director | 1.5yrs | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Independent Director | 4.17yrs | US$150.74k | 1.91% $ 45.4m | |
| Independent Director | 1.67yrs | no data | no data |
1.6yrs
Average Tenure
48yo
Average Age
Experienced Board: CRON's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CRON insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
Top Shareholders
Company Information
Cronos Group Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cronos Group Inc.
- Ticker: CRON
- Exchange: TSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$2.376b
- Shares outstanding: 349.89m
- Website: https://www.thecronosgroup.com
Number of Employees
Location
- Cronos Group Inc.
- 720 King Street West
- Suite 320
- Toronto
- Ontario
- M5V 2T3
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRON | TSX (The Toronto Stock Exchange) | Yes | New Common Shares | CA | CAD | Dec 2014 |
| CRON | NasdaqGM (Nasdaq Global Market) | Yes | New Common Shares | US | USD | Dec 2014 |
| 7CI | DB (Deutsche Boerse AG) | Yes | New Common Shares | DE | EUR | Dec 2014 |
Biography
Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, ret ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/26 06:11 |
| End of Day Share Price | 2020/09/25 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.